Treatment of pediatric plasma cell myeloma type post‐transplant lymphoproliferative disorder with modern risk‐directed therapy |
| |
| Authors: | Rebecca Epperly John Ozolek Kyle Soltys Debra Cohen Rakesh Goyal Erika Friehling |
| |
| Affiliation: | 1. Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee;2. Department of Pathology, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania;3. Thomas E. Starzl Transplantation Institute, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania;4. Pediatric Hematology‐Oncology, University of Florida, Pensacola, Florida;5. Department of Hematology/Oncology/BMT, Children's Mercy, Kansas City, Missouri;6. Division of Pediatric Hematology/Oncology, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania |
| |
| Abstract: | ![]()
Post‐transplant lymphoproliferative disorder (PTLD) related plasma cell neoplasms are rare in pediatric patients. We report a pediatric liver transplant recipient with plasma cell myeloma type PTLD. Cytogenetics included 1q duplication, associated with poor prognosis in adult multiple myeloma, and t(8;14). High‐risk cytogenetics has not been reported in pediatric plasma cell myeloma type PTLD. The patient was treated with bortezomib, dexamethasone, and lenalidomide with subsequent autologous stem cell transplant. He achieved a 6‐year remission, demonstrating tolerance to and efficacy of this modern myeloma regimen in a pediatric patient. Unfortunately, he subsequently died from complications of repeat liver transplant. |
| |
| Keywords: | bortezomib cytogenetics lenalidomide multiple myeloma post‐transplant lymphoproliferative disorder |
|
|
